Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents

Peripheral T-cell lymphoma (PTCL) is characterized by clinicopathologic heterogeneity with a frequently relapsing/refractory (R/R) course. The optimal sequencing and efficacy of novel agents and SCT in second-line and beyond remains yet to be determined. The objective of this dual-institution retrospective study is to assess outcomes in R/R nodal PTCL with respect to SCT and novel agents. A total of 148 patients were reviewed for baseline characteristics and treatment parameters. Endpoints were subsequent EFS (sEFS) and subsequent overall survival (sOS). The median sEFS and sOS for the entire cohort was 5.3 m (95% CI: 4.1 - 7.1) and 32.4 m (95% CI: 17.7 - 71.0), respectively. The median sEFS favored patients who received salvage SCT following either chemotherapy or novel agents (<i>p</i> = 0.005). The median sOS showed similar trend. Altogether, these data suggest that incorporation of novel agents in patients with and without SCT in second-line and beyond may improve outcomes compared to historical cohorts.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2025-08-14
DOI
https://doi.org/10.1080/10428194.2025.2540437
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents

Hua-Jay Jeffery Cherng, Giorgio Inghirami, Ahmed Sawas, Barbara Pro et al.
1 citations
Leukemia & lymphoma/Leukemia and lymphoma
Lymphoma Diagnosis and Treatment
1.47
article

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents

Hua-Jay Jeffery Cherng, Giorgio Inghirami, Ahmed Sawas, Barbara Pro, Madhav Seshadri, Caitlin Gribbin, Koen van Besien, Adrienne A. Phillips, Jia Ruan, Evelyn Orlando, Seda S. Tolu, Tsiporah B. Shore, Jennifer E. Amengual, Alexander Sanjurjo, Justin E. Grenet, Zhengming Chen, Rajbir Toor, Peter W. Martin, John P. Leonard
article en
1 citations

Abstract

Peripheral T-cell lymphoma (PTCL) is characterized by clinicopathologic heterogeneity with a frequently relapsing/refractory (R/R) course. The optimal sequencing and efficacy of novel agents and SCT in second-line and beyond remains yet to be determined. The objective of this dual-institution retrospective study is to assess outcomes in R/R nodal PTCL with respect to SCT and novel agents. A total of 148 patients were reviewed for baseline characteristics and treatment parameters. Endpoints were subsequent EFS (sEFS) and subsequent overall survival (sOS). The median sEFS and sOS for the entire cohort was 5.3 m (95% CI: 4.1 - 7.1) and 32.4 m (95% CI: 17.7 - 71.0), respectively. The median sEFS favored patients who received salvage SCT following either chemotherapy or novel agents (<i>p</i> = 0.005). The median sOS showed similar trend. Altogether, these data suggest that incorporation of novel agents in patients with and without SCT in second-line and beyond may improve outcomes compared to historical cohorts.

Leukemia & lymphoma/Leukemia and lymphomaVol. 66(13)
Cornell University (US), Columbia University Irving Medical Center (US), College Medical Center (US), Weill Cornell Medical College in Qatar (QA), Sylvester Comprehensive Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 16%
Lymphoma Diagnosis and Treatment
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.